Myelofibrosis associated with systemic lupus erythematosus successfully treated with rituximab

Abstract

Get full access to this article

View all access options for this article.

References

Hepburn

Nair

Mason

. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology 2010; 49: 2243–2254.

Pereira

RMR

Velloso

ERP

Menezes

Gualandro

Vassalo

Yoshinari

. Bone marrow findings in systemic lupus erythematosus patients with peripheral cytopenias. Clin Rheumatol 1998; 17: 219–222.

Wanitpongpun

Teawtrakul

Mahakkanukrauh

Siritunyaporn

Sirijerachai

Chansung

. Bone marrow abnormalities in systemic lupus erythematosus with peripheral cytopenia. Clin Exp Rheumatol 2012; 30: 825–829.

Marcellino

El Jamal

Mascarenhas

. Distinguishing autoimmune myelofibrosis from primary myelofibrosis. Clin Adv Hematol Oncol 2018; 16: 619–626.

Chalayer

Ffrench

Cathébras

. Bone marrow fibrosis as a feature of systemic lupus erythematosus: a case report and literature review. Springerplus 2014; 3: 349–349.

Del Porto

Tatarelli

Di Napoli

Proietta

. Systemic lupus erythematosus and myelofibrosis: a case report and revision of literature. Leuk Res Rep 2018; 9: 58–64.

Hasrouni

Rogers

Tabarroki

, et al. A case of mistaken identity: when lupus masquerades as primary myelofibrosis. SAGE Open Med Case Rep 2013; 1: 2050313X13498709–2050313X13498709.

Kvasnicka

Beham-Schmid

Bob

, et al. Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis – a consensus-based study. Histopathology 2016; 68: 905–915. DOI: 10.1111/his.12871.

Pirone

Mendoza-Pintob

Van Der Windt

Parker

O’Sullivan

Bruce

. Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): a systematic review. Semin Arthritis Rheum 2017; 47: 384–396.

10.

Vital

Dass

Buch

, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2010; 63: 3038–3047.

11.

Porpaczy

Tripolt

Hoelbl-Kovacic

, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood 2018; 132: 694–706.